Owners, management and financials
CVR: 10048818
Secondary names: AROS Applied Biotechnology A/S, Eurofins Genomics Europe Genotyping A/S, GENOSKAN A/S
Previous names: AROS APPLIED BIOTECHNOLOGY ApS, AROS APPLIED BIOTECHNOLOGY A/S, Eurofins Genomics Europe Genotyping A/S
DKK 43,634,455
Gross profit
Net result: DKK -8,643,885
Eurofins Genomics LUX Holding SARL (100%)
CVR · view owners
Jacob Sickmann Ransborg
Board: Svend Aage Linde (chair) and 2 members
CVR · view management
Active
Founded 1 November 2000
CVR · view overview
68 employees
CVR · 2026
Name registered: Eurofins Genomics Denmark A/S
CVR · 16/05/2025
View the full event history
Eurofins Genomics Denmark A/S is a Danish company of the type Aktieselskab based in Galten, founded in 2000. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Eurofins Genomics Europe AgriGenomics Products & Services A/S and Eurofins Genomics Europe Genotyping A/S. The management consists of Jacob Sickmann Ransborg. The board consists of Svend Aage Linde (chair), Jacob Sickmann Ransborg and Ulrich August Werner Kühle. The company is owned by Eurofins Genomics LUX Holding SARL. The company has 68 employees (2026). In 2025, the company reported a gross profit of DKK 43,634,455 and a net result of DKK -8,643,885 compared with DKK -12,812,295 the year before. Equity in the 2025 report amounted to DKK 14,211,619.
Source: annual report 2025, Danish Business Authority
The financial health of Eurofins Genomics Denmark A/S shows a concerning trend, with significant fluctuations in profitability over recent years. While gross profit peaked at 104.25 million DKK in 2021, it has since declined to 43.63 million DKK in 2025, with mounting losses, particularly a notable loss of 20.74 million DKK in 2023. The company's equity position has also deteriorated, swinging from 49.85 million DKK in 2021 to 14.21 million DKK in 2025, indicating potential financial instability. Despite its established presence in the research and experimental development sector, ongoing losses and declining equity raise concerns about its long-term viability and operational efficiency.
AI-generated summary · Generated 14/08/2026
Selskabets formål er kontraktforskning, laboratoriemæssig service og handel med knowhow og laboratorieydelser.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 43.6 mio. | -8.6 mio. | 143.1 mio. | 14.2 mio. | 64 | |
| 202401/01/2024 – 31/12/2024 | 36.8 mio. | -12.8 mio. | 175.3 mio. | -4.1 mio. | 62 | |
| 202301/01/2023 – 31/12/2023 | 17.3 mio. | -20.7 mio. | 134.5 mio. | 17.8 mio. | 56 | |
| 202201/01/2022 – 31/12/2022 | 27.2 mio. | -12.9 mio. | 77 mio. | 15.9 mio. | 68 | |
| 202101/01/2021 – 31/12/2021 | 104.3 mio. | 32.4 mio. | 123.9 mio. | 49.9 mio. | 101 | |
| 202001/01/2020 – 31/12/2020 | 40.9 mio. | 11.5 mio. | 105.8 mio. | 23 mio. | 42 | |
| 201901/01/2019 – 31/12/2019 | 14.6 mio. | -4.9 mio. | 50.3 mio. | 5 mio. | 41 | |
| 201801/01/2018 – 31/12/2018 | 14.8 mio. | -1.1 mio. | 40.1 mio. | 9.9 mio. | - | |
| 201701/01/2017 – 31/12/2017 | 14.5 mio. | 963 t. | 44.1 mio. | 11.8 mio. | - | |
| 201601/01/2016 – 31/12/2016 | 12 mio. | -3.9 mio. | 43.9 mio. | 10.8 mio. | - | |
| 201501/01/2015 – 31/12/2015 | 19.9 mio. | -1.6 mio. | 49.9 mio. | 16.8 mio. | 26 | |
| 201401/01/2014 – 31/12/2014 | 27 mio. | 4.8 mio. | 36.4 mio. | 20.4 mio. | - | |
| 201301/01/2013 – 31/12/2013 | 22.2 mio. | 2.2 mio. | 50.7 mio. | 17.1 mio. | - | |
| 201201/01/2012 – 31/12/2012 | 22.5 mio. | 3.4 mio. | 46.1 mio. | 14.9 mio. | - |
Compared to 1.038 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Eurofins Genomics Denmark A/S is 10048818.
Eurofins Genomics Denmark A/S is owned by Eurofins Genomics LUX Holding SARL.
The management of Eurofins Genomics Denmark A/S consists of Jacob Sickmann Ransborg.
The board of Eurofins Genomics Denmark A/S consists of Svend Aage Linde, Jacob Sickmann Ransborg and Ulrich August Werner Kühle, with Svend Aage Linde as chair.
In 2025, Eurofins Genomics Denmark A/S reported a gross profit of DKK 43,634,455.
Eurofins Genomics Denmark A/S had 68 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Eurofins Genomics Denmark A/S has published its annual report for 2025. Gross profit came to DKK 43,634,455, and the net result was DKK -8,643,885.
Eurofins Genomics Denmark A/S has published its annual report for 2024. Gross profit came to DKK 36,823,021, and the net result was DKK -12,812,295.
On May 16, 2025, the company changed its name from Eurofins Genomics Europe AgriGenomics Products & Services A/S to Eurofins Genomics Denmark A/S.
As of May 1, 2025, is registered as an owner of Eurofins Genomics Denmark A/S with an ownership share of 100%.
Eurofins Genomics Denmark A/S has published its annual report for 2023. Gross profit came to DKK 17,330,918, and the net result was DKK -20,741,913.
As of March 1, 2024, Ulrich August Werner Kühle has joined the board of directors of Eurofins Genomics Denmark A/S.
As of February 29, 2024, Sonja Maria Wiedemann has left the board of directors of Eurofins Genomics Denmark A/S.
As of July 1, 2023, Sonja Maria Wiedemann has joined the board of directors of Eurofins Genomics Denmark A/S.
As of July 1, 2023, Michael Hadem has left the board of directors of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2022. Gross profit came to DKK 27,205,625, and the net result was DKK -12,918,322.
On March 9, 2023, the company changed its name from Eurofins Genomics Europe Genotyping A/S to Eurofins Genomics Europe AgriGenomics Products & Services A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2021. Gross profit came to DKK 104,253,154, and the net result was DKK 32,351,392.
Eurofins Genomics Denmark A/S has published its annual report for 2020. Gross profit came to DKK 40,931,581, and the net result was DKK 11,534,393.
As of May 27, 2021, Jacob Sickmann Ransborg has joined the board of directors of Eurofins Genomics Denmark A/S.
As of May 27, 2021, Stefánia Pcolová has left the board of directors of Eurofins Genomics Denmark A/S.
As of July 17, 2020, Michael Hadem has joined the board of directors of Eurofins Genomics Denmark A/S.
As of July 17, 2020, Bruno Francis Claude Poddevin has left the board of directors of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2019. Gross profit came to DKK 14,555,825, and the net result was DKK -4,940,253.
Eurofins Genomics Denmark A/S has published its annual report for 2018. Gross profit came to DKK 14,758,474, and the net result was DKK -1,133,413.
As of May 15, 2019, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Eurofins Genomics Denmark A/S.
As of May 15, 2019, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Eurofins Genomics Denmark A/S.
On January 3, 2019, the company changed its name from AROS APPLIED BIOTECHNOLOGY A/S to Eurofins Genomics Europe Genotyping A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2017. Gross profit came to DKK 14,526,644, and the net result was DKK 963,492.
As of June 11, 2018, Jacob Sickmann Ransborg is registered as adm. dir. of Eurofins Genomics Denmark A/S.
As of June 11, 2018, Daniel Schougaard Langhoff has stepped down as adm. dir. of Eurofins Genomics Denmark A/S.
As of January 26, 2018, Stefánia Pcolová has joined the board of directors of Eurofins Genomics Denmark A/S.
As of January 1, 2018, Thomas Gjelsnes has left the board of directors of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2016. Gross profit came to DKK 12,026,280, and the net result was DKK -3,936,856.
As of January 1, 2017, Daniel Schougaard Langhoff is registered as adm. dir. of Eurofins Genomics Denmark A/S.
As of December 31, 2016, Morten Melbye has left the board of directors of Eurofins Genomics Denmark A/S.
As of December 31, 2016, Morten Melbye has stepped down as adm. dir. of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2015. Gross profit came to DKK 19,851,375, and the net result was DKK -1,613,388.
As of May 30, 2016, Morten Melbye has joined the board of directors of Eurofins Genomics Denmark A/S.
As of August 13, 2015, Thomas Gjelsnes has joined the board of directors of Eurofins Genomics Denmark A/S.
As of August 13, 2015, Lars Christian Caspersen has left the board of directors of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2014. Gross profit came to DKK 27,048,886, and the net result was DKK 4,781,470.
As of May 27, 2015, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Eurofins Genomics Denmark A/S.
As of May 27, 2015, AP STATSAUTORISEREDE REVISORER P/S has stepped down as auditor of Eurofins Genomics Denmark A/S.
As of May 27, 2015, Torben Falck Ørntoft has left the board of directors of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2013. Gross profit came to DKK 22,186,118, and the net result was DKK 2,228,041.
As of September 1, 2013, Morten Melbye is registered as adm. dir. of Eurofins Genomics Denmark A/S.
As of September 1, 2013, Brian Sørensen has stepped down as adm. dir. of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S has published its annual report for 2012. Gross profit came to DKK 22,504,216, and the net result was DKK 3,393,255.
As of February 20, 2013, Torben Falck Ørntoft has joined the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Svend Aage Linde has joined the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Lars Christian Caspersen has joined the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Bruno Francis Claude Poddevin has joined the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Niels Stampe Rüdiger has left the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Jørgen Winther Pedersen has left the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Kurt Hedegaard Carstensen has left the board of directors of Eurofins Genomics Denmark A/S.
As of February 20, 2013, Villy Helleskov has left the board of directors of Eurofins Genomics Denmark A/S.
As of January 1, 2013, AP STATSAUTORISEREDE REVISORER P/S has been appointed auditor of Eurofins Genomics Denmark A/S.
As of December 31, 2012, ALBERT PEDERSEN. STATSAUTORISEREDEREVISORER I/S has stepped down as auditor of Eurofins Genomics Denmark A/S.
As of March 21, 2011, Kurt Hedegaard Carstensen has joined the board of directors of Eurofins Genomics Denmark A/S.
As of September 24, 2010, ALBERT PEDERSEN. STATSAUTORISEREDEREVISORER I/S has been appointed auditor of Eurofins Genomics Denmark A/S.
As of September 24, 2010, A/S PSE NR. 4820 has stepped down as auditor of Eurofins Genomics Denmark A/S.
As of September 24, 2010, Carsten Kultoft Lorentsen has left the board of directors of Eurofins Genomics Denmark A/S.
As of May 20, 2009, Niels Stampe Rüdiger has joined the board of directors of Eurofins Genomics Denmark A/S.
As of May 20, 2009, Carsten Kultoft Lorentsen has joined the board of directors of Eurofins Genomics Denmark A/S.
As of May 20, 2009, Brian Sørensen is registered as adm. dir. of Eurofins Genomics Denmark A/S.
As of May 20, 2009, Torben Falck Ørntoft has stepped down as director of Eurofins Genomics Denmark A/S.
As of September 11, 2007, Arne Josefsen Rolighed has left the board of directors of Eurofins Genomics Denmark A/S.
As of March 2, 2007, A/S PSE NR. 4820 has been appointed auditor of Eurofins Genomics Denmark A/S.
As of March 2, 2007, A/S PSE NR. 4820 has stepped down as auditor of Eurofins Genomics Denmark A/S.
As of February 9, 2007, Claus Thorsen has left the board of directors of Eurofins Genomics Denmark A/S.
On April 11, 2005, the company changed its name from AROS APPLIED BIOTECHNOLOGY ApS to AROS APPLIED BIOTECHNOLOGY A/S.
As of December 1, 2004, Jørn Renz Enggaard has left the board of directors of Eurofins Genomics Denmark A/S.
As of November 18, 2003, Jørgen Winther Pedersen has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 18, 2003, Arne Josefsen Rolighed has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 18, 2003, Torben Falck Ørntoft has left the board of directors of Eurofins Genomics Denmark A/S.
As of November 18, 2003, Mogens Kruhøffer has left the board of directors of Eurofins Genomics Denmark A/S.
As of March 13, 2002, Claus Thorsen has joined the board of directors of Eurofins Genomics Denmark A/S.
As of March 13, 2002, Villy Helleskov has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 1, 2000, A/S PSE NR. 4820 has been appointed auditor of Eurofins Genomics Denmark A/S.
As of November 1, 2000, Torben Falck Ørntoft has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 1, 2000, Jørn Renz Enggaard has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 1, 2000, Mogens Kruhøffer has joined the board of directors of Eurofins Genomics Denmark A/S.
As of November 1, 2000, Torben Falck Ørntoft is registered as director of Eurofins Genomics Denmark A/S.
Eurofins Genomics Denmark A/S was founded on November 1, 2000.
Companies in the same industry and area
CVR 46568354
CVR 32958583
CVR 26555450
CVR 33871805
CVR 42894192
